Abstract
The development of new phamacological treatments for obesity has been challenging. In part, the lack of early diagnosis, early detection, early intervention and treatment has meant that more cases progress to life-threatening co-morbidities and surgical options. Pharmacological treatment of obesity has been limited. Self medication with drugs of abuse and tobacco has been successful for some patients, but abuse and addiction make this approach quite dangerous. The advent of trendy ‘diets du jour’ has apparently made obesity and eating disorders more likely rather than less likely. Trials of novel anti-obesity compounds have generally compared the new medication and placebo to a dietary counseling intervention. Interventions for patients who are not obese enough for gastric banding or bariatric surgery are quite similar to those given to alcoholics in the 1970s, “drink less or stop drinking”. We need to consume less in a modern life of desk and computer work, driving, and even internet shopping. However, we are driven and reinforced to consume and easily fall prey to television and other cues and messages driving this relationship to eating. This paper , after briefly reviewing the consensus on consumption and exercising suggests that new treatments may be developed by increasing exercise adherence and even increasing the reinforcing value or power of exercise itself. Food, sex, and drugs of abuse are highly valued and reinforced in our brains, so why not exercise?
Keywords: Obesity, exercise, aerobic, resistance, anorexia, globesity, tobacco, medication, epidemic, astounding, hedonic, plethora, starvation, adolescents, bariatric surgery, pedometers
Current Pharmaceutical Design
Title: Exercise for the Overweight and Obese
Volume: 17 Issue: 12
Author(s): Jessica Gold and Mark S. Gold
Affiliation:
Keywords: Obesity, exercise, aerobic, resistance, anorexia, globesity, tobacco, medication, epidemic, astounding, hedonic, plethora, starvation, adolescents, bariatric surgery, pedometers
Abstract: The development of new phamacological treatments for obesity has been challenging. In part, the lack of early diagnosis, early detection, early intervention and treatment has meant that more cases progress to life-threatening co-morbidities and surgical options. Pharmacological treatment of obesity has been limited. Self medication with drugs of abuse and tobacco has been successful for some patients, but abuse and addiction make this approach quite dangerous. The advent of trendy ‘diets du jour’ has apparently made obesity and eating disorders more likely rather than less likely. Trials of novel anti-obesity compounds have generally compared the new medication and placebo to a dietary counseling intervention. Interventions for patients who are not obese enough for gastric banding or bariatric surgery are quite similar to those given to alcoholics in the 1970s, “drink less or stop drinking”. We need to consume less in a modern life of desk and computer work, driving, and even internet shopping. However, we are driven and reinforced to consume and easily fall prey to television and other cues and messages driving this relationship to eating. This paper , after briefly reviewing the consensus on consumption and exercising suggests that new treatments may be developed by increasing exercise adherence and even increasing the reinforcing value or power of exercise itself. Food, sex, and drugs of abuse are highly valued and reinforced in our brains, so why not exercise?
Export Options
About this article
Cite this article as:
Gold Jessica and S. Gold Mark, Exercise for the Overweight and Obese, Current Pharmaceutical Design 2011; 17 (12) . https://dx.doi.org/10.2174/138161211795656729
DOI https://dx.doi.org/10.2174/138161211795656729 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Skeletal Muscle Protein Balance and Metabolism in the Elderly
Current Aging Science The General Practitioners Role in Promoting Physical Activity to Older Adults: A Review Based on Program Theory
Current Aging Science Rationally Designed Multitarget Agents Against Inflammation and Pain
Current Medicinal Chemistry A Hyperlipidemic Diet Induces Structural Changes in Cerebral Blood Vessels
Current Neurovascular Research The Role on Endoscopy in Alcohol-Related Diseases
Reviews on Recent Clinical Trials The Protective Role of Crocus Sativus L. (Saffron) Against Ischemia- Reperfusion Injury, Hyperlipidemia and Atherosclerosis: Nature Opposing Cardiovascular Diseases
Current Cardiology Reviews Modifiable Risk Factors Associated with Alzheimer’s Disease with Special Reference to Sleep Disturbance
CNS & Neurological Disorders - Drug Targets Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches
Current Pharmaceutical Design Diagnosis, Treatment, and New Developments in Preeclampsia
Current Women`s Health Reviews Protein Z and Ischemic Stroke
Vascular Disease Prevention (Discontinued) Placental Drug Disposition and Its Clinical Implications
Current Drug Metabolism Functional Genomics of the Oxidative Stress Pathway
Current Hypertension Reviews Recent Patents on Microbial Proteases for the Dairy Industry
Recent Advances in DNA & Gene Sequences (Discontinued) Design and Ocular Tolerance of Flurbiprofen Loaded Nanosuspension
Pharmaceutical Nanotechnology Losartan Chemistry and Its Effects via AT1 Mechanisms in the Kidney
Current Medicinal Chemistry Adverse Effects of Tacrolimus in Renal Transplant Patients from Living Donors
Current Drug Safety Melatonin and Respiratory Diseases: A Review
Current Topics in Medicinal Chemistry Current Concepts in SLE Thrombocytopenia: From Pathophysiology to Therapeutic Interventions
Current Rheumatology Reviews Pharmacotherapy of Abdominal Aortic Aneurysms
Current Vascular Pharmacology Editorial (Thematic Issue: NADPH Oxidase-Derived ROS Signaling and Therapeutic Opportunities)
Current Pharmaceutical Design